Midostaurin for FLT3-mutated AML: a real-world analysis of effectiveness and infection risk at a single center.

Kennedy, Alice; Patel, Shyam; Ramanathan, Muthalagu; Gerber, Jonathan; Cerny, Jan

Kennedy, Alice; Patel, Shyam; Ramanathan, Muthalagu; Gerber, Jonathan; Cerny, Jan.

Afiliación

Kennedy A; Tufts Medical Center, Department of Internal Medicine, Boston, MA, USA.
Patel S; University of Massachusetts Chan Medical School, Worcester, MA, USA.
Ramanathan M; Division of Hematology and Oncology, Department of Internal Medicine, UMass Memorial Health Care, Worcester, MA, USA.
Gerber J; Division of Hematology and Oncology, Department of Internal Medicine, UMass Memorial Health Care, Worcester, MA, USA.
Cerny J; Division of Hematology and Oncology, Department of Internal Medicine, UMass Memorial Health Care, Worcester, MA, USA.

Ann Hematol ; 103(3): 1031-1033, 2024 Mar.

Article en En | MEDLINE | ID: mdl-38195923

Asunto(s)

Leucemia Mieloide Aguda; Inhibidores de Proteínas Quinasas; Estaurosporina/análogos & derivados; Humanos; Estaurosporina/uso terapéutico; Leucemia Mieloide Aguda/tratamiento farmacológico; Leucemia Mieloide Aguda/genética; Tirosina Quinasa 3 Similar a fms/genética; Mutación

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Leucemia Mieloide Aguda / Estaurosporina / Inhibidores de Proteínas Quinasas Tipo de estudio: Etiology_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Ann Hematol Asunto de la revista: HEMATOLOGIA Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google